Tetramer Assay for Measuring T-Cell Responses

Antigen Panels for Monitoring Cellular Immune Response

The Serametrix Tetramer Assay measures T-cell activation to tumor antigens. Using patented tetramer technologies and reagents from the Ludwig Institute for Cancer Research (LICR), this assay measures a patient’s cellular immune response to specific panels of tumor antigens, and can reveal the relationship between T-cell activation and clinical outcome to immunotherapy (1,2).

Tetramer Assay components:

The Serametrix Tetramer Assay includes study design, tetramer assay, and results with comprehensive analysis and interpretation. Disease-specific panels include:

  • Breast cancer
  • Colorectal cancer
  • Glioblastoma
  • Melanoma
  • Non-small cell lung cancer
  • Pancreatic cancer
  • Prostate cancer
  • Renal cell carcinoma
  • Ovarian cancer

For most disease panels it is possible to measure not only CD8+ cytotoxic T-cell responses but also CD4+ helper T-cells. In addition, the range of patient haplotypes that can be measured is increasing, with almost complete patient coverage for the leading cancer types.

To discuss ideas for your study or request a quote, click here.

 

(1) Yuan et al (2011). Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. PNAS, Vol. 108, No. 40, pp 16723-16728.
(2) Yuan et al (2008). CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. PNAS, Vol. 105, No. 51, pp 20410-20415.
 

Contact us today to learn how Serametrix can improve your results.

©2017 Serametrix  l  US: +1-760-652-4060  l  Europe: +44 (0)20 8973 3853 | info@serametrix.com

Go to top